Dicerna Pharmaceuticals, Inc.

Shanthi Ganesh

Marc Abrams

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a &#x3b2;-catenin inhibitor, a therapeutically effective amount of an IDO inhibitor, and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a &#x3b2;-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an IDO inhibitor and an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a &#x3b2;-catenin inhibitor, such as a &#x3b2;-catenin nucleic acid inhibitor molecule, in combination with an IDO inhibitor.

Reducing beta-catenin and IDO expression to potentiate immunotherapy

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a &#x3b2;-catenin inhibitor and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a &#x3b2;-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a &#x3b2;-catenin inhibitor, such as a &#x3b2;-catenin nucleic acid inhibitor molecule.

Reducing beta-catenin expression to potentiate immunotherapy

Disclosed herein are methods for the treatment of cancer, comprising administering to a subject &#x3b2;-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of &#x3b2;-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.

Compositions and methods for the treatment of a beta-catenin-associated disease or disorder

Provided herein is a potent, optimized &#x3b2;-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides. Also provided are methods and compositions for reducing &#x3b2;-catenin expression and methods and compositions for treating cancer.

Beta catenin nucleic acid inhibitor molecule

Disclosed herein are methods for the treatment of cancer, comprising administering to a subject a &#x3b2;-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule. Also disclosed herein is a pharmaceutical composition comprising a therapeutically effective amount of a &#x3b2;-catenin nucleic acid inhibitor molecule; a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule and at least one pharmaceutical carrier.

Growing community of inventors

Shrewsbury, MA, United States of America

Shanthi Ganesh